Chang Lisa | TaiRx, Inc. | New Drug Development

A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA.

2018/3/8 TaiRx, Inc. (6580) announces today that its new injection product, Zelnite®, received NDA approval from the Taiwan FDA on January 22nd, 2018. [...]

A first in Taiwan! In collaboration with Taiwanese API and drug product manufacturers, TaiRx produced the first domestically manufactured selenium trace element drug in Taiwan and was approved by the Taiwan FDA. Chang Lisa 2021-03-11T15:36:59+00:00

TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta.

2017/10/31 Lee WJ, Chen YL, Chu YW, Chien DS. Comparison of glutathione peroxidase-3 protein expression and enzyme bioactivity in normal subjects and patients with sepsis. Clin Chim Acta. [...]

TaiRx published study results of serum GPx-3 protein levels and associated bioactivity in healthy subjects and sepsis patients in Clinica Chimica Acta. Chang Lisa 2018-06-04T17:52:42+00:00

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer.

2017/8/22 TaiRx Announces License Agreement with Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago, for Nodal Patents to Develop [...]

TaiRx and Northwestern University Ann & Robert H. Lurie Children’s Hospital completed exclusive licensing deal for global development and market rights using Nodal protein as new biomarker to detect malignant tumor also for the treatment of various metastatic cancer. Chang Lisa 2018-06-04T17:50:31+00:00

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June.

2017/6/15 TaiRx shows its potential in new cancer drug development and will be listed on the emerging stock market on June 20th. […]

TaiRx held a pre-IPO institutional investors’ conference and announced the listing on Taiwan Emerging Market on the 20th of June. Chang Lisa 2018-06-04T17:50:50+00:00

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO

2017/6/5 TaiRx, Inc. (6580) publishes its Phase I clinical trial result in the United States and Taiwan on CVM-1118, a new cancer drug, at [...]

TaiRx presents CVM-1118 Phase I Clinical Trial Progress at ASCO Chang Lisa 2018-06-04T17:50:56+00:00

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer.

2016/06/17 This issue of Science magazine (June 17, 2016) featured a column on how malignant tumor cells avoid traditional anti-angiogenesis mechanism and achieve metastasis. [...]

Science reported TaiRx’s CVM-1118 as the first drug entering clinical trial, inhibiting the formation of vasculogenic mimicry in cancer. Chang Lisa 2018-06-04T17:51:02+00:00

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition.

2015/9/24 […]

TaiRx received Honorable award at the 2015 Taiwan Healthcare and Agricultural Biotech Industries Innovation and Excellence Award Competition. Chang Lisa 2021-02-17T13:44:45+00:00

About Chang Lisa